Proteins for life
ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.
The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.
Latest press release
ExpreS2ion will participate in key investor events in December 2021
Hørsholm, Denmark, November 29, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in December. These include events hosted by Aktiespararna and HC Andersen Capital in collaboration with Nordea Markets.
Read more